Type	type	O	O	OTHERS	I
B	b	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
after	after	O	O	O	O
needle-stick	needle-stick	O	O	O	O
exposure	exposure	O	O	O	O
:	:	O	O	O	O
prevention	prevention	O	O	O	O
with	with	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
immune	immune	O	O	O	O
globulin	globulin	O	O	O	O
.	.	O	O	O	O

Final	final	O	O	O	O
report	report	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
Veterans	veterans	O	O	O	O
Administration	administration	O	O	O	O
Cooperative	cooperative	O	O	O	O
Study	study	O	O	O	O
.	.	O	O	O	O

Hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
immune	immune	O	O	O	O
globulin	globulin	O	O	O	O
(	(	O	O	O	O
HBIG	hbig	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
immune	immune	O	O	O	O
serum	serum	O	O	O	O
globulin	globulin	O	O	O	O
(	(	O	O	O	O
ISG	isg	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
examined	examined	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
trial	trial	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
their	their	O	O	O	O
relative	relative	O	O	O	O
efficacies	efficacies	O	O	O	O
in	in	O	O	O	O
preventing	preventing	O	O	O	O
type	type	O	O	OTHERS	I
B	b	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
after	after	O	O	O	O
needle-stick	needle-stick	O	O	O	O
exposure	exposure	O	O	O	O
to	to	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
surface	surface	O	O	OTHERS	I
antigen	antigen	O	O	OTHERS	I
(HBsAG)-positive	(hbsag)-positive	O	O	O	O
donors	donors	O	O	O	O
.	.	O	O	O	O

Clinical	clinical	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
developed	developed	O	O	O	O
in	in	O	O	O	O
1.4	1.4	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
HBIG	hbig	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
5.9	5.9	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
ISG	isg	O	O	O	O
recipients	recipients	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
0.016	0.016	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
seroconversion	seroconversion	O	O	O	O
(	(	O	O	O	O
anti-HBs	anti-hbs	O	O	O	O
)	)	O	O	O	O
occurred	occurred	O	O	O	O
in	in	O	O	O	O
5.6	5.6	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
20.7	20.7	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
them	them	O	O	O	O
respectively	respectively	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
less	less	O	O	O	O
than	than	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Mild	mild	O	O	O	O
and	and	O	O	O	O
transient	transient	O	O	O	O
side-effects	side-effects	O	O	O	O
were	were	O	O	O	O
noted	noted	O	O	O	O
in	in	O	O	O	O
3.0	3.0	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
ISG	isg	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
3.2	3.2	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
HBIG	hbig	O	O	O	O
recipients	recipients	O	O	O	O
.	.	O	O	O	O

Available	available	O	O	O	O
donor	donor	O	O	O	O
sera	sera	O	O	O	O
were	were	O	O	O	O
examined	examined	O	O	O	O
for	for	O	O	O	O
DNA	dna	O	O	O	O
polymerase	polymerase	O	O	O	O
(	(	O	O	O	O
DNAP	dnap	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
e	e	O	O	OTHERS	I
antigen	antigen	O	O	O	O
and	and	O	O	O	O
antibody	antibody	O	O	O	O
(	(	O	O	O	O
HBeAg	hbeag	CHEMICALS	O	OTHERS	I
;	;	O	O	O	O
anti-HBE	anti-hbe	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Both	both	O	O	O	O
DNAP	dnap	O	O	O	O
and	and	O	O	O	O
HBeAg	hbeag	CHEMICALS	O	OTHERS	I
showed	showed	O	O	O	O
a	a	O	O	O	O
highly	highly	O	O	O	O
statistically	statistically	O	O	O	O
significant	significant	O	O	O	O
correlation	correlation	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
infectivity	infectivity	O	O	O	O
of	of	O	O	O	O
HBsAg-positive	hbsag-positive	O	O	O	O
donors	donors	O	O	O	O
.	.	O	O	O	O

Hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
immune	immune	O	O	O	O
globulin	globulin	O	O	O	O
remained	remained	O	O	O	O
significantly	significantly	O	O	O	O
superior	superior	O	O	O	O
to	to	O	O	O	O
ISG	isg	O	O	O	O
in	in	O	O	O	O
preventing	preventing	O	O	O	O
type	type	O	O	OTHERS	I
B	b	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
even	even	O	O	O	O
when	when	O	O	O	O
the	the	O	O	O	O
analysis	analysis	O	O	O	O
was	was	O	O	O	O
confined	confined	O	O	O	O
to	to	O	O	O	O
these	these	O	O	O	O
two	two	O	O	O	O
high-risk	high-risk	O	O	O	O
subgroups	subgroups	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
efficacy	efficacy	O	O	O	O
of	of	O	O	O	O
ISG	isg	O	O	O	O
in	in	O	O	O	O
preventing	preventing	O	O	O	O
type	type	O	O	OTHERS	I
B	b	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
can	can	O	O	O	O
not	not	O	O	O	O
be	be	O	O	O	O
ascertained	ascertained	O	O	O	O
because	because	O	O	O	O
a	a	O	O	O	O
true	true	O	O	O	O
placebo	placebo	O	O	O	O
group	group	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
included	included	O	O	O	O
.	.	O	O	O	O

